Current treatments used in clinical practice for major depressive disorder and treatment resistant depression in England: A retrospective database study
- PMID: 34077893
- DOI: 10.1016/j.jpsychires.2021.05.026
Current treatments used in clinical practice for major depressive disorder and treatment resistant depression in England: A retrospective database study
Abstract
Background: Major depressive disorder (MDD) is a chronic recurrent or episodic psychiatric illness that can be successfully treated with oral antidepressants, yet one-in-three patients do not respond to currently-available treatments. According to the FDA and EMA, patients are considered to have treatment-resistant depression (TRD) when their MDD fails to respond adequately to ≥2 successive antidepressants in a single episode.
Aims: To describe current clinical management of patients with MDD and TRD in England, including treatment strategies and referral to secondary mental healthcare.
Method: A retrospective cohort study of adult patients identified in primary care with diagnosed MDD, including a TRD subgroup (≥2 treatment failures as determined by treatment dynamics) was conducted using the Clinical Practice Research Datalink GOLD primary care database linked to Hospital Episode Statistics and Mental Health Services Data Set data (Protocol 19_019R).
Results: 41,375 patients with MDD (mean age 44yrs, 62% female, median follow-up 29mths); and 1,051 (3%) patients with TRD were identified. Mean time-to-TRD was 18 months. Most patients (>99%) received first-line antidepressant monotherapy. Following TRD criteria being met, antidepressant monotherapy use remained most frequent from TRD first-line (70%) to fifth-line (48%). Dual/triple antidepressant use remained constant (range:24%-26%), while augmented antidepressant use increased from TRD first-line (7%) to third-line (17%). Minimal non-pharmacological therapies were observed.
Conclusions: Despite current clinical guidelines recommending a stepwise approach, many patients frequently cycle through numerous antidepressants with similar mechanisms of action and efficacy. These findings indicate a high unmet need for new treatments that improve outcomes in these patient populations.
Keywords: Clinical practice research datalink (CPRD); England; Hospital episode statistics [HES]; Major depressive disorder; Mental health services data set (MHSDS); Population-based study; Treatment resistant depression.
Copyright © 2021. Published by Elsevier Ltd.
Similar articles
-
A clinical approach to treatment resistance in depressed patients: What to do when the usual treatments don't work well enough?World J Biol Psychiatry. 2021 Sep;22(7):483-494. doi: 10.1080/15622975.2020.1851052. Epub 2020 Dec 8. World J Biol Psychiatry. 2021. PMID: 33289425
-
Association of Treatment-Resistant Depression With Patient Outcomes and Health Care Resource Utilization in a Population-Wide Study.JAMA Psychiatry. 2023 Feb 1;80(2):167-175. doi: 10.1001/jamapsychiatry.2022.3860. JAMA Psychiatry. 2023. PMID: 36515938 Free PMC article.
-
Trajectories of pharmacological therapies for treatment-resistant depression: a longitudinal study.BMC Psychiatry. 2025 Mar 10;25(1):215. doi: 10.1186/s12888-025-06518-8. BMC Psychiatry. 2025. PMID: 40065240 Free PMC article.
-
Novel antidepressant drugs: Beyond monoamine targets.CNS Spectr. 2023 Feb;28(1):6-15. doi: 10.1017/S1092852921000791. Epub 2021 Sep 30. CNS Spectr. 2023. PMID: 34588093 Review.
-
Combination therapy with monoamine oxidase inhibitors and other antidepressants or stimulants: strategies for the management of treatment-resistant depression.Pharmacotherapy. 2015 Apr;35(4):433-49. doi: 10.1002/phar.1576. Pharmacotherapy. 2015. PMID: 25884531 Review.
Cited by
-
Impact of moderate-to-high-suicide-intent in major depressive disorder: a retrospective cohort study on patient characteristics and healthcare resource utilisation in England.BMC Psychiatry. 2024 Aug 23;24(1):576. doi: 10.1186/s12888-024-05961-3. BMC Psychiatry. 2024. PMID: 39180055 Free PMC article.
-
Efficacy and Safety of Esketamine Combined with Antidepressants for Treatment-Resistant Depression: A Meta-Analysis.Neuropsychiatr Dis Treat. 2022 Dec 7;18:2855-2865. doi: 10.2147/NDT.S388764. eCollection 2022. Neuropsychiatr Dis Treat. 2022. PMID: 36514492 Free PMC article. Review.
-
Care pathways, prescribing practices and treatment outcomes in major depressive disorder and treatment-resistant depression: retrospective, population-based cohort study.BJPsych Open. 2024 Jan 19;10(1):e32. doi: 10.1192/bjo.2023.627. BJPsych Open. 2024. PMID: 38240079 Free PMC article.
-
Association between polypharmacy and depression relapse in individuals with comorbid depression and type 2 diabetes: a UK electronic health record study.Br J Psychiatry. 2023 Mar;222(3):112-118. doi: 10.1192/bjp.2022.160. Br J Psychiatry. 2023. PMID: 36451601 Free PMC article.
-
Selective Serotonin Reuptake Inhibitors for the Treatment of Depression in Adults with Down Syndrome: A Preliminary Retrospective Chart Review Study.Brain Sci. 2021 Sep 15;11(9):1216. doi: 10.3390/brainsci11091216. Brain Sci. 2021. PMID: 34573236 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous